The use of sodium carboxymethylcellulose in the preparation of spray-dried proteins for pulmonary drug delivery

European Journal of Pharmaceutical Sciences

Volumn 40, Issue 1, 2010, Pages 56-61

  Li, Hao Ying ^a   Song, Xiaosong ^a   Seville, Peter C ^a  

^a ASTON UNIVERSITY   (United Kingdom)

Author keywords

DPI; HFA 134a; PMDI; Protein; Sodium carboxymethylcellulose; Spray drying

Indexed keywords

ALKALINE PHOSPHATASE; CARBOXYMETHYLCELLULOSE; AEROSOL; EXCIPIENT; FLUORINATED HYDROCARBON; NORFLURANE; POWDER; PROTEIN;

AEROSOL; ARTICLE; CHEMICAL MODIFICATION; CONTROLLED STUDY; DRUG FORMULATION; DRUG STORAGE; DRY POWDER; INTERMETHOD COMPARISON; METERED DOSE INHALER; PARTICLE SIZE; PHYSICAL CHEMISTRY; POWDER INHALER; PRIORITY JOURNAL; SPRAY DRYING; ANIMAL; BOVINAE; CHEMISTRY; DRUG DELIVERY SYSTEM; ENZYME STABILITY; INHALATIONAL DRUG ADMINISTRATION; POWDER; PROCEDURES; SCANNING ELECTRON MICROSCOPY;

ADMINISTRATION, INHALATION; AEROSOLS; ALKALINE PHOSPHATASE; ANIMALS; CARBOXYMETHYLCELLULOSE; CATTLE; DRUG DELIVERY SYSTEMS; ENZYME STABILITY; EXCIPIENTS; HYDROCARBONS, FLUORINATED; METERED DOSE INHALERS; MICROSCOPY, ELECTRON, SCANNING; PARTICLE SIZE; POWDERS; PROTEINS; CARBOXYMETHYLCELLULOSE SODIUM;

EID: 77951209180     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejps.2010.02.007     Document Type: Article

References (32)

1. Adi H., Traini D., Chan H.K., Young P.M. The influence of drug morphology on aerosolisation efficiency of dry powder inhaler formulations. J. Pharm. Sci. 2008, 97:2780-2788.
2. Bosquillon C., Rouxhet P.G., Ahimou F., Simon D., Culot C., Préat V., Vanbever R. Aerosolization properties, surface composition and physical state of spray-dried protein powders. J. Control. Release 2004, 99:357-367.
3. Brown A.R., George D.W. Tetrafluoroethane (HFC 134a) propellant-driven aerosols of proteins. Pharm. Res. 1997, 14:1542-1547.
4. Chan H.K., Clark A.R., Feeley J.C., Kuo M.C., Lehrman S.R., Pikal-Cleland K., Miller D.P., Vehring R., Lechuga-Ballesteros D. Physical stability of salmon calcitonin spray-dried powders for inhalation. J. Pharm. Sci. 2004, 93:792-804.
5. Chew N.Y., Chan H.K. Use of solid corrugated particles to enhance powder aerosol performance. Pharm. Res. 2001, 18:1570-1577.
6. Engstrom J.D., Tam J.M., Miller M.A., Williams R.O., Johnston K.P. Templated open flocs of nanorods for enhanced pulmonary delivery with pressurized metered dose inhalers. Pharm. Res. 2009, 26:101-117.
7. Evans R.M., Farr S.J., Armstrong N.A., Chatham S.M. Formulation and in vitro evaluation of pressurized inhalation aerosols containing isotropic systems of lecithin and water. Pharm. Res. 1991, 8:629-635.
8. Griesenbach U., Meng C., Farley R., Wasowicz M.Y., Munkonge F.M., Chan M., Stoneham C., Sumner-Jones S.G., Pringle I.A., Gill D.R., Hyde S.C., Stevenson B., Holder E., Ban H., Hasegawa M., Cheng S.H., Scheule R.K., Sinn P.L., McCray P.B., Alton E.W. The use of carboxymethylcellulose gel to increase non-viral gene transfer in mouse airways. Biomaterials 2009, 10.1016/j.biomaterials.2009.12.005.
9. Harris H. The human alkaline phosphatases: what we know and what we don't know. Clin. Chim. Acta 1990, 186:133-150.
10. Jalalipour M., Gilani K., Tajerzadeh H., Najafabadi A.R., Barghi M. Characterization and aerodynamic evaluation of spray dried recombinant human growth hormone using protein stabilizing agents. Int. J. Pharm. 2008, 352:209-216.
11. Jones S.A., Martin G.P., Brown M.B. Stabilisation of deoxyribonuclease in hydrofluoroalkanes using miscible vinyl polymers. J. Control. Release 2006, 115:1-8.
12. Keegan A. Exit Exubera. Inhalable insulin is withdrawn due to weak sales. Diabetes Forecast 2007, 60:19.
13. Lenzer J. Inhaled insulin is approved in Europe and United States. Br. Med. J. 2006, 332:321.
14. Li H.Y., Birchall J. Chitosan-modified dry powder formulations for pulmonary gene delivery. Pharm. Res. 2006, 23:941-950.
15. Li H.Y., Seville P.C. Novel pMDI formulations for pulmonary delivery of proteins. Int. J. Pharm. 2010, 385:73-78.
16. Li H.Y., Neill H., Innocent R., Seville P., Williamson I., Birchall J.C. Enhanced dispersibility and deposition of spray-dried powders for pulmonary gene therapy. J. Drug Target. 2003, 11:425-432.
17. Li H.Y., Seville P.C., Williamson I.J., Birchall J.C. The use of absorption enhancers to enhance the dispersibility of spray-dried powders for pulmonary gene therapy. J. Gene Med. 2005, 7:1035-1043.
18. Liao Y.H., Brown M.B., Jones S.A., Nazir T., Martin G.P. The effects of polyvinyl alcohol on the in vitro stability and delivery of spray-dried protein particles from surfactant-free HFA 134a-based pressurised metered dose inhalers. Int. J. Pharm. 2005, 304:29-39.
19. Ludwig A. The use of mucoadhesive polymers in ocular drug delivery. Adv. Drug Deliv. Rev. 2005, 57:1595-1639.
20. Myrdal P.B., Karlage K.L., Stein S.W., Brown B.A., Haynes A. Optimized dose delivery of the peptide cyclosporine using hydrofluoroalkane-based metered dose inhalers. J. Pharm. Sci. 2004, 93:1054-1061.
21. Parsons D. Carboxymethylcellulose sodium. Handbook of Pharmaceutical Excipients 2000, 87-90. Pharmaceutical Press, London, UK. 3rd edition. A.H. Kibbe (Ed.).
22. Rabbani N.R., Seville P.C. The influence of formulation components on the aerosolisation properties of spray-dried powders. J. Control. Rel. 2005, 110:130-140.
23. Rau J.L. The inhalation of drugs: advantages and problems. Respir. Care 2005, 50:367-382.
24. Rokhade A.P., Agnihotri S.A., Patil S.A., Mallikarjuna N.N., Kulkarni P.V., Aminabhavi T.M. Semi-interpenetrating polymer network microspheres of gelatin and sodium carboxymethyl cellulose for controlled release of ketorolac tromethamine. Carbohydr. Polym. 2006, 65:243-252.
25. Seville P.C., Kellaway I.W., Birchall J.C. Preparation of dry powder dispersions for non-viral gene delivery by freeze-drying and spray-drying. J. Gene Med. 2002, 4:428-437.
26. Shoyele S.A., Slowey A. Prospects of formulating proteins/peptides as aerosols for pulmonary drug delivery. Int. J. Pharm. 2006, 314:1-8.
27. Sinn P.L., Shah A.J., Donovan M.D., McCray P.B. Viscoelastic gel formulations enhance airway epithelial gene transfer with viral vectors. Am. J. Respir. Cell Mol. Biol. 2005, 32:404-410.
28. Spoto G., Fioroni M., Rubini C., Tripodi D., Di Stilio M., Piattelli A. Alkaline phosphatase activity in normal and inflamed dental pulps. J. Endod. 2001, 27:180-182.
29. Thiel C.G. From Susie's question to CFC free: an inventor's perspective on forty years of MDI development and regulation. Respiratory Drug Delivery V 1996, 115-123. Interpharm Press, Buffalo Grove, IL. R.N. Dalby, P.R. Byron, S.J. Farr (Eds.).
30. Thipphawong J. Inhaled cytokines and cytokine antagonists. Adv. Drug Deliv. Rev. 2006, 58:1089-1105.
31. Williams R.O., Liu J. Formulation of a protein with propellant HFA 134a for aerosol delivery. Eur. J. Pharm. Sci. 1999, 7:137-144.
32. Yang M., Velaga S., Yamamoto H., Takeuchi H., Kawashima Y., Hovgaard L., van de Weert M., Frokjaer S. Characterisation of salmon calcitonin in spray-dried powder for inhalation. Effect of chitosan. Int. J. Pharm. 2007, 331:176-181.